Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients

Next Previous
X
Search
Trial Profile

A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aprepitant (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Sponsors Merck & Co

    • Most Recent Events

    • 02 Sep 2015 According to Merck & Co. media release, supplemental NDA for aprepitant (EMEND) in combination with other antiemetics has been approved by the US FDA for use in patients 12 years of age and older and patients less than 12 years who weigh at least 30 kg for the prevention of chemotherapy induced nausea and vomiting based partly on data from this trial.
    • 22 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 30 Apr 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top